Real-World study eyes drug combo for tough prostate cancer

NCT ID NCT07674121

Not yet recruiting Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study observes how well a combination of two drugs, olaparib and abiraterone, works as a first treatment for men with metastatic castration-resistant prostate cancer who have already tried other hormone therapies. Researchers will track how long patients stay on the treatment and how long before they need another therapy. The goal is to gather real-world data from the GCC region to inform future treatment guidelines.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olaparib and abiraterone combination
What this could lead to: If successful, this study could provide real-world evidence to support using this drug combination earlier in treatment for men with metastatic prostate cancer.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It is also small (75 participants) and limited to the GCC region, which may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.